Menu
Recruiting NCT07349498

Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation

— Observational Hematopoietic Stem Cell Transplantation Transplant Complication Cardiovascular Events

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT): A Prospective Multicenter Observational Study

Overview

This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.

Primary outcome measures

  • Major adverse cardiovascular events (MACE) [Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.]
Secondary outcome measures (4)
  • Cardiovascular events [Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.]
  • Overall survival [Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.]
  • Event-free survival [Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.]
  • Complications of hematopoietic stem cell transplantation [Time frame: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.]

Eligibility criteria

Inclusion criteria

  • Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.

Exclusion criteria

  • Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
  • Patient request to withdraw from the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 16 centers
  • Chinese PLA General Hospital — Beijing
  • Peking University First Hospital — Beijing
  • Peking University People's Hospital — Beijing
  • Peking University Third Hospital — Beijing
  • Xinqiao hospital of the third military medical university — Chongqing
  • Sun Yat-sen University Cancer Center, Sun Yat-sen University — Guangzhou
  • Peking University Shenzhen Hospital — Shenzhen
  • First Affiliated Hospital of Harbin Medical University — Harbin
  • … and 8 more centers

Identifiers

NCT: NCT07349498 · 2025-z232

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗